145 related articles for article (PubMed ID: 34347311)
1. Investigating the antifibrotic potential of N-acetyl seryl-aspartyl-lysyl-proline sequence peptides.
Ramasamy V; Ntsekhe M; Sturrock E
Clin Exp Pharmacol Physiol; 2021 Nov; 48(11):1558-1565. PubMed ID: 34347311
[TBL] [Abstract][Full Text] [Related]
2. Interaction of N-acetyl-seryl-aspartyl-lysyl-proline with the angiotensin-converting enzyme 2-angiotensin-(1-7)-Mas axis attenuates pulmonary fibrosis in silicotic rats.
Gao X; Xu H; Zhang B; Tao T; Liu Y; Xu D; Cai W; Wei Z; Li S; Zhang H; Mao N; Zhang G; Li D; Jin F; Li S; Zhang L; Liu H; Hao X; Yang F
Exp Physiol; 2019 Oct; 104(10):1562-1574. PubMed ID: 31290182
[TBL] [Abstract][Full Text] [Related]
3. d-amino acid modification protects N-Acetyl-seryl-aspartyl-lysyl-proline from physiological hydroxylation and increases its antifibrotic effects on hepatic fibrosis.
Zhang X; Zhou J; Zhu Y; He L; Pang Z; Wang Z; Xu C; Zhang C; Hao Q; Li W; Zhang W; Zhang Y; Li M
IUBMB Life; 2019 Sep; 71(9):1302-1312. PubMed ID: 30900390
[TBL] [Abstract][Full Text] [Related]
4. Antifibrotic effect of Ac-SDKP and angiotensin-converting enzyme inhibition in hypertension.
Rasoul S; Carretero OA; Peng H; Cavasin MA; Zhuo J; Sanchez-Mendoza A; Brigstock DR; Rhaleb NE
J Hypertens; 2004 Mar; 22(3):593-603. PubMed ID: 15076166
[TBL] [Abstract][Full Text] [Related]
5. Prevention of myocardial fibrosis by N-acetyl-seryl-aspartyl-lysyl-proline in diabetic rats.
Castoldi G; di Gioia CR; Bombardi C; Perego C; Perego L; Mancini M; Leopizzi M; Corradi B; Perlini S; Zerbini G; Stella A
Clin Sci (Lond); 2009 Oct; 118(3):211-20. PubMed ID: 20310083
[TBL] [Abstract][Full Text] [Related]
6. N-Acetyl-seryl-aspartyl-lysyl-proline inhibits TGF-beta-mediated plasminogen activator inhibitor-1 expression via inhibition of Smad pathway in human mesangial cells.
Kanasaki K; Koya D; Sugimoto T; Isono M; Kashiwagi A; Haneda M
J Am Soc Nephrol; 2003 Apr; 14(4):863-72. PubMed ID: 12660320
[TBL] [Abstract][Full Text] [Related]
7. Effect of N-acetyl-seryl-aspartyl-lysyl-proline on DNA and collagen synthesis in rat cardiac fibroblasts.
Rhaleb NE; Peng H; Harding P; Tayeh M; LaPointe MC; Carretero OA
Hypertension; 2001 Mar; 37(3):827-32. PubMed ID: 11244003
[TBL] [Abstract][Full Text] [Related]
8. Renal antifibrotic effect of N-acetyl-seryl-aspartyl-lysyl-proline in diabetic rats.
Castoldi G; di Gioia CR; Bombardi C; Preziuso C; Leopizzi M; Maestroni S; Corradi B; Zerbini G; Stella A
Am J Nephrol; 2013; 37(1):65-73. PubMed ID: 23327833
[TBL] [Abstract][Full Text] [Related]
9. Renal release of N-acetyl-seryl-aspartyl-lysyl-proline is part of an antifibrotic peptidergic system in the kidney.
Romero CA; Kumar N; Nakagawa P; Worou ME; Liao TD; Peterson EL; Carretero OA
Am J Physiol Renal Physiol; 2019 Jan; 316(1):F195-F203. PubMed ID: 30403163
[TBL] [Abstract][Full Text] [Related]
10. N-acetyl-seryl-aspartyl-lysyl-proline mediates the anti-fibrotic properties of captopril in unilateral ureteric obstructed BALB/C mice.
Chan GCW; Wu HJ; Chan KW; Yiu WH; Zou A; Huang XR; Lan HY; Lai KN; Tang SCW
Nephrology (Carlton); 2018 Apr; 23(4):297-307. PubMed ID: 28075040
[TBL] [Abstract][Full Text] [Related]
11. Antifibrotic effects of N-acetyl-seryl-aspartyl-Lysyl-proline on the heart and kidney in aldosterone-salt hypertensive rats.
Peng H; Carretero OA; Raij L; Yang F; Kapke A; Rhaleb NE
Hypertension; 2001 Feb; 37(2 Pt 2):794-800. PubMed ID: 11230375
[TBL] [Abstract][Full Text] [Related]
12. Prevention of aortic fibrosis by N-acetyl-seryl-aspartyl-lysyl-proline in angiotensin II-induced hypertension.
Lin CX; Rhaleb NE; Yang XP; Liao TD; D'Ambrosio MA; Carretero OA
Am J Physiol Heart Circ Physiol; 2008 Sep; 295(3):H1253-H1261. PubMed ID: 18641275
[TBL] [Abstract][Full Text] [Related]
13. A long-acting isomer of Ac-SDKP attenuates pulmonary fibrosis through SRPK1-mediated PI3K/AKT and Smad2 pathway inhibition.
Qiu Y; Wang Z; Zhang X; Huang P; Zhang W; Zhang K; Wang S; He L; Guo Y; Xiang A; Zhang C; Hao Q; Li M; Li W; Zhang Y
IUBMB Life; 2020 Dec; 72(12):2611-2626. PubMed ID: 33135306
[TBL] [Abstract][Full Text] [Related]
14. High plasma level of N-acetyl-seryl-aspartyl-lysyl-proline: a new marker of chronic angiotensin-converting enzyme inhibition.
Azizi M; Ezan E; Nicolet L; Grognet JM; Ménard J
Hypertension; 1997 Nov; 30(5):1015-9. PubMed ID: 9369248
[TBL] [Abstract][Full Text] [Related]
15. The Effects of Angiotensin Converting Enzyme Inhibitors (ACE-I) on Human N-Acetyl-Seryl-Aspartyl-Lysyl-Proline (Ac-SDKP) Levels: A Systematic Review and Meta-Analysis.
Mnguni AT; Engel ME; Borkum MS; Mayosi BM
PLoS One; 2015; 10(12):e0143338. PubMed ID: 26656271
[TBL] [Abstract][Full Text] [Related]
16. N-acetyl-seryl-aspartyl-lysyl-proline prevents renal insufficiency and mesangial matrix expansion in diabetic db/db mice.
Shibuya K; Kanasaki K; Isono M; Sato H; Omata M; Sugimoto T; Araki S; Isshiki K; Kashiwagi A; Haneda M; Koya D
Diabetes; 2005 Mar; 54(3):838-45. PubMed ID: 15734863
[TBL] [Abstract][Full Text] [Related]
17. N-acetyl-seryl-aspartyl-lysyl-proline (Ac-SDKP): Potential target molecule in research of heart, kidney and brain.
Hrenak J; Paulis L; Simko F
Curr Pharm Des; 2015; 21(35):5135-43. PubMed ID: 26350537
[TBL] [Abstract][Full Text] [Related]
18. N-acetyl-seryl-aspartyl-lysyl-proline ameliorates the progression of renal dysfunction and fibrosis in WKY rats with established anti-glomerular basement membrane nephritis.
Omata M; Taniguchi H; Koya D; Kanasaki K; Sho R; Kato Y; Kojima R; Haneda M; Inomata N
J Am Soc Nephrol; 2006 Mar; 17(3):674-85. PubMed ID: 16452498
[TBL] [Abstract][Full Text] [Related]
19. Angiotensin-converting enzyme inhibitors: a new mechanism of action.
Peng H; Carretero OA; Vuljaj N; Liao TD; Motivala A; Peterson EL; Rhaleb NE
Circulation; 2005 Oct; 112(16):2436-45. PubMed ID: 16216963
[TBL] [Abstract][Full Text] [Related]
20. Prolyl oligopeptidase is involved in release of the antifibrotic peptide Ac-SDKP.
Cavasin MA; Rhaleb NE; Yang XP; Carretero OA
Hypertension; 2004 May; 43(5):1140-5. PubMed ID: 15037553
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
